Ask us a question 520 547-3440 info@c-path.org

Subscribe

Donate

Home
About
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS

BmDR

Biomarker Data Repository

PRO Consortium

Patient-Reported Outcome Consortium

CPAD

Critical Path for Alzheimer’s Disease

PKDOC

Polycystic Kidney Disease Outcomes Consortium

CPP

Critical Path for Parkinson’s

PredicTox KE

PredicTox Knowledge Environment

CP-SCD

Critical Path for Sickle Cell Disease

PSTC

Predictive Safety Testing Consortium

CPTA

Critical Path to Therapeutics for the Ataxias

QuantMed

Quantitative Medicine Program

CDRC

CURE Drug Repurposing Collaboratory

RDCA-DAP

Rare Disease Cures Accelerator-Data and Analytics Platform

DCC

Data Collaboration Center

RD-COA Consortium

Rare Disease Clinical Outcome Assessment Consortium

D-RSC

Duchenne Regulatory Science Consortium

TB-PACTS

TB-Platform for Aggregation of Clinical TB Studies

eCOA Consortium

Electronic Clinical Outcome Assessment Consortium

TTC

Transplant Therapeutics Consortium

FA-ICD

Friedreich’s Ataxia Integrated Clinical Database

TOMI-T1D

Trial Outcome Markers Initiative in T1D Consortium

HD-RSC

Huntington’s Disease Regulatory Science Consortium

TRxA

Translational Therapeutics Accelerator

INC

International Neonatal Consortium

T1D

Type 1 Diabetes Consortium

MSOAC

Multiple Sclerosis Outcome Assessments Consortium

Completed Consortia

CFAST

Coalition for Accelerating Standards & Therapies

PTC

Pediatric Trials Consortium

CPTR

Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Impact
News & Events
- Events
- News
- Videos
- Publications
- Presentations
- Press Releases
Education

News

Home>News & Events>Imbria Pharmaceuticals

News

October 17, 2019 PRINT PDF

Imbria Pharmaceuticals

Obtaining and Using TPOXX (Tecovirimat) for the Treatment of Monkeypox
Workshop: Accelerating Medical Product Development in Kidney Transplantation Through a Public-private Partnership
Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies
Register Now: DIA 2022 Digital Technology in Clinical Trials Conference
Register Now | Addressing the Gaps in Clinical Trial Readiness for FSHD

Annual Reports
Contact
Donate
Employment
Explore C-Path
FAQs
FDA Acknowledgement
Policies
GDPR SCCs
Privacy Policy
Terms of Use

C-Path Main Office 1730 E. River Rd., #200
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456 C-Path Global Ltd. 33 Sir John Rogerson’s
Dublin 2, Ireland

Ask us a question Tel: 520-547¬3440
Email: info@c-path.org Subscribe

x

News

News

Imbria Pharmaceuticals

Related Posts